"10.1371_journal.pone.0020606","plos one","2011-08-11T00:00:00Z","Victoria O Kasprowicz; Jessica E Mitchell; Shivan Chetty; Pamla Govender; Kuan-Hsiang Gary Huang; Helen A Fletcher; Daniel P Webster; Sebastian Brown; Anne Kasmar; Kerry Millington; Cheryl L Day; Nompumelelo Mkhwanazi; Cheryl McClurg; Fundisiwe Chonco; Ajit Lalvani; Bruce D Walker; Thumbi Ndung'u; Paul Klenerman","Ragon Institute of MGH, MIT and Harvard, Harvard Medical School, Boston, Massachusetts, United States of America; Kwazulu-Natal Research Institute for TB and HIV, Nelson R. Mandela School of Medicine, Durban, South Africa; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, Durban, South Africa; Nuffield Department of Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom; Nuffield Department of Medicine, Oxford Biomedical Research Centre and James Martin School for 21st Century, University of Oxford, Oxford, United Kingdom; Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America; Tuberculosis Research Unit, Department of Respiratory Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom","Conceived and designed the experiments: VOK PK HAF DPW AL. Performed the experiments: JEM SC PG K-HGH NM CLD SB CM. Analyzed the data: VOK JEM SC PK. Contributed reagents/materials/analysis tools: BDW TN AL VOK KM. Wrote the paper: VOK JEM PK AL KM AK. Physician for patients in South Africa: FC. Responsible for providing clinical information to the study: FC. Study clinician: FC. Performed some of the assays on the study: NM.","The authors do not have a commercial or other association that might pose a conflict of interest. However, it should be noted that Professor Lalvani is an inventor with several patents underpinning T cell-based diagnosis. The ESAT-6/CFP-10 IFN-gamma ELISpot assay was commercialised by an Oxford University spin-out company (T-SPOT.TBÂ®, Oxford Immunotec Ltd, Abingdon, UK) in which the University of Oxford and Professor Lalvani have minority shares of equity and royalty entitlements.","2011","08","Victoria O Kasprowicz","VOK",18,TRUE,5,8,4,6,TRUE,TRUE,FALSE,0,NA,FALSE
